Haemonetics (HAE)
(Delayed Data from NYSE)
$76.15 USD
+0.21 (0.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$76.15 USD
+0.21 (0.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Here's Why You Should Retain Haemonetics (HAE) Stock for Now
by Zacks Equity Research
Strong recovery across businesses and strength in plasma franchise benefited Haemonetics (HAE) during the first quarter of fiscal 2022.
Company News for Aug 12, 2021
by Zacks Equity Research
Companies In The News Are: WEN, HAE, RPRX, BLI
Haemonetics (HAE) Q1 Earnings Top Estimates, Margins Improve
by Zacks Equity Research
Ongoing recovery in businesses, especially Hospital, and the initial Plasma Persona rollouts drove Haemonetics (HAE) fiscal first-quarter revenues.
Haemonetics (HAE) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 6.38% and 1.33%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Haemonetics (HAE) Q4 Earnings Lag Estimates, Gross Margin Dips
by Zacks Equity Research
Haemonetics' (HAE) fourth-quarter fiscal 2021 revenues declined 5.6% year over year due to the pandemic.
Haemonetics (HAE) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of -31.34% and -0.06%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Continued benefits from the NexSys device and NexLynk DMS along with robust TEG devices sales are expected to have contributed to Haemonetics (HAE) fourth-quarter top line.
Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omnicell's (OMCL) 2025 Roadmap Impressive, Pandemic Woe Stays
by Zacks Equity Research
Omnicell (OMCL) expands its autonomous pharmacy portfolio with the acquisition of PSG's 340B Link business.
Reasons to Hold on to Syneos Health (SYNH) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery of its operating segments and strategic partnerships.
Here's Why You Should Add Haemonetics (HAE) to Your Portfolio
by Zacks Equity Research
Investor are optimistic about Haemonetics (HAE) on its continued Plasma franchise growth and huge potential of Hemostasis Management franchise.
Haemonetics (HAE) Down 5.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics (HAE) Q3 Earnings Top Estimates, Margin Contracts
by Zacks Equity Research
Haemonetics (HAE) third-quarter fiscal 2021 revenues declined 7.2% year over year to $240.4 million, improving 14.7% sequentially.
Haemonetics (HAE) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 19.12% and 6.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stock Earnings on Feb 2: IDXX, MCK & More
by Urmimala Biswas
In Q4, MedTech stocks are expected to have gained from month-wise sales rebound in many states and regions. However, international sales might have been dampened.
PerkinElmer (PKI) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results are likely to reflect strong performance at Diagnostics segment.
McKesson (MCK) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.
Haemonetics (HAE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ABIOMED (ABMD) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
The strong momentum of ABIOMED's (ABMD) Impella product line, both in Europe and Japan, is expected to have continued in the fiscal third quarter as well.
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
BD's (BDX) first-quarter fiscal 2021 results are likely to reflect strong year-over-year growth in revenues from assays in its Life Sciences segment.
Stryker (SYK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) fourth-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
Varian (VAR) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Varian's (VAR) fiscal first-quarter earnings are likely to reflect strength in Halcyon platform.
Haemonetics (HAE) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Haemonetics (HAE) is optimistic about maintaining a robust product portfolio amid the pandemic-led business disruptions.
What's in Store for Intuitive Surgical's (ISRG) Q4 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter earnings are likely to reflect solid performance at Instruments & Accessories segment.